Investor Presentaiton

Clinical Development Pipeline Next generation GDT cell therapies for both solid tumors and blood cancers Program Indication OmnImmune (V82 subtype) AML Allogeneic (Unmodified) Pre-clinical Phase 1 Phase 2 Phase 3 Status / Upcoming Milestone TCB-008 (V82 subtype) AML 1b Allogeneic (Unmodified) Anti-Bacterical/Anti- Fungal 2b TC BIOPHARM Phase 1b/2a complete H1 2020 - PR & CR achieved Phase 2b launched, 5 patients dosed to date Announced FDA Clearance of Phase 1B IND for TCB-008 Proof of Concept & Pre-clinical Work Program that does not involve any current development or clinical activity by the Company Program Indication TCB001 Autologous Melanoma (Unmodified) Pre-clinical Phase 1 Phase 2 Phase 3 Status / Upcoming Milestone Phase 1b/2a POC complete - evidence of tumor shrinkage (not pursuing further development) 5

View entire presentation